- Home
- ICCM vs NRXP Comparison
ICCM vs NRXP Comparison
Compare ICCM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | NRXP |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 54.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICCM | NRXP |
|---|---|---|
| Price | $0.67 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.50 | ★ $31.50 |
| AVG Volume (30 Days) | 136.9K | ★ 493.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.87 | N/A |
| Revenue Next Year | $31.38 | $847.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.58 |
| 52 Week High | $1.53 | $3.84 |
Technical Indicators
Market Signals| Indicator | ICCM | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 58.32 | 47.54 |
| Support Level | $0.58 | $1.65 |
| Resistance Level | $0.74 | $1.99 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 67.81 | 53.97 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.